news on paul sekhri news home advertising board and executive moves energy health care hedge funds m  a private equity technology person paul sekhri ▼ topic all topics ▼ organizations find news about organizations alumni find news on alumni of any org industries find news on a particular market your contacts find news on your contacts sign up for free daily alerts on this feed by pressing sign up you agree to our terms of use privacy policy and the lexisnexis terms  conditions follow change feed paul sekhri lycera announces the appointment of pablo j cagnoni md to the board of directors march    •  pr newswire  several lifechanging medicines for people with cancer and other debilitating diseases said paul sekhri president and ceo of lycera we believe both his experience as  lycera announces initiation of phase a study argon of immunooncology candidate lyc in patients with advanced solid tumors january    •  pr newswire   months and our first immunooncology compound to enter the clinic said paul sekhri president and ceo of lycera the promising results of our preclinical  lycera announces initiation of phase  uprise clinical trial of lycec for patients with moderate psoriasis december    •  pr newswire  a gutdirected therapy to target the treatment of peripheral autoimmune disease said paul sekhri president and ceo of lycera based upon the results of our  lycera announces appointments of leading experts to scientific advisory board november    •  pr newswire  the most important and rapidly changing disciplines within the health sciences said paul sekhri president and ceo of lycera lycera is dedicated to developing innovative  lycera announces initiation of phase  clinical trial of lycec in patients with ulcerative colitis august    •  pr newswire   as we build our portfolio of novel immune modulatory treatments said paul sekhri president and ceo of lycera based upon the results of our  lycera congratulates dr peter l toogood for his receipt of the  heroes of chemistry award from the american chemical society acs august    •  pr newswire  and innovation we have established at lycera to advance novel immunotherapies said paul sekhri president and ceo of lycera his role as an inventor of  lycera announces progress in immunooncology program presented at the  american association for cancer research aacr annual meeting april    •  pr newswire  rationale for combinations of rorgamma agonists with other immune oncology agents said paul sekhri president and ceo of lycera these findings continue to support the  versant ventures strengthens global team april    •  business wire  new york citybased highline therapeutics added cso joe vacca and operating partner paul sekhri these leadership additions will be critical to our global biotech investment  um spinoff lycera starts anticancer drug trials march    •  crains detroit business  they will decide in the nottoodistant future not years and years said paul sekhri lyceras president and ceo who joined the company in february   lycera announces presentations of positive preclinical results for lead candidate lyc and for selective rho kinase inhibitor program at the th congress of the european crohns and colitis organization ecco march    •  pr newswire  a phase  program in patients with ulcerative colitis later this year paul sekhri president and ceo of lycera corp stated we are very pleased  regeneron cellectis flagship ventures and others headline newyorkbio  ceo breakfast club series february    •  business wire  breakfast club features the following great speakers andre choulika ceo cellectis february paul sekhri ceo lycera april neil stahl evp regeneron april thong le ceo  lycera announces celgene has exercised its option to license portfolio of ex vivo rorgamma agonist compounds under global strategic collaboration january    •  pr newswire   studies of an oral selective rorgamma agonist later this year said paul sekhri president and ceo of lycera corp we also look forward to  lycera announces progress in immunooncology program to be presented at society for immunotherapy of cancer sitc  annual meeting november    •  pr newswire  and away from immune suppression and the persistence of memory cells said paul sekhri president and ceo of lycera these and other key findings point  lycera corp expands leadership team appoints alex g howarth as chief financial officer october    •  pr newswire  accounting financial planning and strategic analysis mr howarth will report directly to paul sekhri lyceras president and ceo and his appointment is effective immediately alex  distinguished pharma leaders and experienced investors join together in nuvelution pharma inc july    •  business wire  former ceos of bayer pharmaceuticals sanofi and teva respectively as well as paul sekhri ceo of lycera and former global bd and chief strategy officer  lycera and celgene announce an exclusive strategic collaboration to advance novel immune modulators june    •  pr newswire  disruptive scientific approaches that can translate into diseasealtering medicines for patients said paul sekhri president and ceo of lycera corp celgene made clear that they  lycera initiates phase  clinical trial of lyc a firstinclass atpase modulator for inflammatory bowel disease april    •  pr newswire  as well as the first atpase modulator to commence clinical testing said paul sekhri president and ceo of lycera corp lycera is dedicated to advancing  lycera announces milestone in merck collaboration march    •  pr newswire  of this milestone with our collaborator merck stated lyceras president and ceo paul sekhri the progress of the program provides further validation of lyceras leadership  enumeral reports fourth quarter and yearend  financial results march    •  business wire  the biotechnology and biopharmaceutical industry to the companys board of directors paul j sekhri president and chief executive officer of lycera corp and robert l  lycera expands leadership team names h jeffrey wilkins md as chief medical officer  dr wilkins to lead advancement of lyceras clinical programs including first clinical trial anticipated to begin in q  march    •  pr newswire  the end of  dr wilkins will report to president and ceo paul sekhri and his appointment is effective immediately we are delighted to welcome  enumeral appoints paul j sekhri to its board of directors february    •  business wire  enumeral biomedical holdings inc otcqb enum announced today it appointed paul j sekhri to its board of directors mr sekhri is an accomplished industry  lycera announces research showing promising anticancer activity of novel oral immunotherapy candidates selective rorgamma agonist product candidates demonstrated activity as single agent therapy february    •  pr newswire  continued successful progress of this program lyceras president and chief executive officer paul sekhri stated lyceras teams possessing worldclass immunology research experience have achieved rapid  lycera names life sciences veteran paul sekhri as president and chief executive officer february    •  pr newswire  lycera names life sciences veteran paul sekhri as president and chief executive officer lycera corp a biopharmaceutical company  life sciences industry veteran paul sekhri joins veeva board of directors july    •  business wire  announcedchanges to its board of directors with the appointment of industry veteran paul sekhri concurrently directors young sohn and kevin spain stepped down a proven  teva expands management team with appointment of paul j sekhri as group executive vice president global business development and chief strategy officer april    •  business wire related news feeds lycera corp pharmaceuticals board and executive moves in pharmaceuticals alumni of university of maryland  school of medicine email linkedin facebook google tweet reddit permalink want to see the full history of news or view news on a particular date upgrade to relsci professional now start my free trial ➤ industry select a topic keyword go  ➤ find an organization select a topic keyword go  ➤ find a person select a topic keyword go  ➤ name of a school or name of an organization select a topic keyword go  ➤ thank you you are now subscribedplease wait for the page to refresh you are now subscribed to this feed you have unsubscribed to this feed thank you you can now subscribe to more relsci news feeds to subscribe to more than one feed please enter a password please confirm your password go  ➤ youve found a premium relsci pro feature follow news on your contacts upgrade to relsci pro now to easily sync your contacts and stay in the know on the news about the people important to you start my free trial ➤ still not convinced check out our full listing of features here not now youve found a premium relsci pro feature search news on keywords curate your news even further with the ability to filter feeds based on specific keywords mentioned in the articles start my free trial ➤ still not convinced check out our full listing of features here not now industries find news on a particular market people find news about people organizations find news about organizations alumni find news on alumni of any org your contacts find news on your contacts free daily alerts sign up for free daily alerts on this feed sign up ➤ by pressing sign up you agree to our terms of use privacy policy and the lexisnexis terms  conditions already have an account click here to login are you a relsci pro subscriber login to relsci pro  ➤ not a pro subscriber log in here to manage your alerts keep me signed in login  ➤ forgot your password i have read the lexisnexis terms  conditions sign me up  ➤ paul sekhri lycera corp profile  biography  bloomberg feedback paul sekhri presidentceo lycera corp career history operating partnerhighline therapeutics versant ventures management llc present presidentceo lycera corp present founder cerimon pharmaceuticals inc present founder cerimon inc present advisor brookings global health financing initiative present directormontrose montrose capital management ltd present senior vpintegrated care sanofi unknown mng dirheadbiotech ops tpg biotech  presidentceofounder cerimon pharmaceuticals inc  preschief business officer ariad pharmaceuticals inc  chairmansupervisory board pharming group nv unknown exec vpbus devchief strategy ofcr teva pharmaceutical industries ltd unknown partner sprout group unknown chairman moksha pharmaceuticals inc former various positions novartis pharma bv former various positions millipore corp former various positions perseptive biosystems inc former founder cerimon pharmaceuticals inc former show more website wwwlyceracom corporate information address  plymouth road ncrc building  ann arbor mi  united states phone  fax  web url wwwlyceracom from the web personal information education university of maryland school of medicine bachelors degree  memberships board memberships aryx therapeutics inc board member present apt pharmaceuticals inc board member present ims health inc board member present cancer research institute board member present tb alliance board member present bioexec institute board member present topas therapeutics gmbh chairman present pharming group nv chairman present nivalis therapeutics inc board member present lycera corp board member present enumeral biomedical holdings inc board member present veeva systems inc board member present intercept pharmaceuticals inc board member unknown kai pharmaceuticals inc board member former affectis pharmaceuticals ag former patientsafe solutions inc board member former tandem diabetics board member former moksha pharmaceuticals inc chairman former macrogenics inc board member former pharming group nv board member unknown pharming group nv board member unknown biodel inc board member unknown show more other memberships patrons council of carnegie hall member sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data paul j sekhri  executive bio compensation history and contacts  equilar atlas   log in  sign up x   as featured in paul j sekhri board member at veeva systems inc view full profile are you paul j sekhri claim your profile   sign up for equilar atlas and view paul j sekhris full profile with equilar atlas you can identify corporate executives in paul j sekhris network and community follow changes in paul j sekhris employment and moneyinmotion connect with paul j sekhri through your network of contacts paul j sekhris executive work history current board member veeva systems inc board member nivalis therapeutics inc board member enumeral biomedical holdings inc past to view paul j sekhris complete executive work history sign up now age      paul j sekhris biography mr sekhri has served as a member of our board since july  since february  mr sekhri has been operating partner at highline therapeutics a biotech incubator launched by versant ventures concurrently and since february  mr sekhri has been president and ceo of lycera corp a biopharmaceutical company prior to joining lycera mr sekhri was senior vice president integrated care at sanofi sa a multinational pharmaceutical company headquartered in france from april  to january  from may  to march  mr sekhri was group executive vice president global business development and chief strategy officer at tev  read more mr sekhri has served as a member of our board since july  since february  mr sekhri has been operating partner at highline therapeutics a biotech incubator launched by versant ventures concurrently and since february  mr sekhri has been president and ceo of lycera corp a biopharmaceutical company prior to joining lycera mr sekhri was senior vice president integrated care at sanofi sa a multinational pharmaceutical company headquartered in france from april  to january  from may  to march  mr sekhri was group executive vice president global business development and chief strategy officer at teva pharmaceutical industries ltd a global pharmaceuticals company focusing on the manufacture of generic and proprietary pharmaceutical products headquartered in israel from january  to may  mr sekhri was operating partner and head biotech ops group at tpg biotech the life sciences venture arm of the global private investment firm tpg capital where he was responsible for a portfolio of more than  life sciences companies from december  to january  mr sekhri was president and ceo of cerimon pharmaceuticals inc a pharmaceutical company focusing on autoimmune diseases and pain management mr sekhri has served as a director of numerous private and public company boards including nivalis therapeutics inc since february  pharming nv since april  enumeral biomedical holdings inc since december  tandem diabetes care inc from may  to may  macrogenics inc from january  to may  and intercept pharmaceuticals inc from january  to september  mr sekhri completed postgraduate studies in clinical anatomy and neuroscience at the university of maryland school of medicine and received a bachelor of science degree in zoology from the university of maryland mr sekhri currently serves on our nominating and governance committee qualifications our board determined that mr sekhri should serve as a director based on his extensive business experience as an executive in the life sciences industry and venture capital experience with respect to the life sciences industry source veeva systems inc on    sign up for equilar atlas and view paul j sekhris full profile by accessing equilar atlas you can view bios network salary and wealth events of industryleading executives like paul j sekhri more specifically youll be able to identify corporate executives in paul j sekhris network and community follow changes in paul j sekhris employment and moneyinmotion connect with paul j sekhri through your network of conections view full profile   search for over  executive profiles bio example paul j sekhri paul j sekhris connections  sign up now to view paul j sekhris  connections » william w george board member the goldman sachs group inc r m carruthers chief financial officer and interim president nivalis therapeutics inc james d wolfensohn former board member magna international inc paul e chamberlain board member trinet group inc john varian dir and former chief executive officer xoma corporation daniel j levitt chief operating officer and chief medical officer cytrx corporation phillip frost board member castle brands inc peter p gassner dir and chief executive officer veeva systems inc matthew j wallach president veeva systems inc timothy s cabral chief financial officer veeva systems inc popular profiles sign up now to view more executive profiles » thomas j lynch executive chairman te connectivity ltd john j kita evp and cfo a o smith elon r musk ceo and chairman tesla daniel a dematteo executive chairman gamestop corp david j oconnor president and ceo the madison square garden company × claim your profile coming soon interested in updating your biography and work history were working on making it happen well email you when this feature is available please enter valid email address done thank you for your interest ok browse executive profiles  a  b  c  d  e  f  g  h  i  j  k  l  m  n  o  p  q  r  s  t  u  v  w  x  y  z equilar homepage equilar atlas equilar insight equilar boardedge equilar engage research services knowledge network about us login �  equilar all rights reserved privacy policy  marshall street redwood city ca   phone    fax   paul j sekhri joins perseptive biosystems as marketing director analytical products  free online library printer friendly  articles and books periodicals literature keyword title author topic the free library  business and industry  business  pr newswire  may   the free library  communications  news opinion and commentary  pr newswire  may   the free library  date      may      pr newswire paul j sekhri joins perseptive biosystems as marketing director analytical products linkpage citation pagelink page url html link a hrefhttpswwwthefreelibrarycompauljsekhrijoinsperseptivebiosystemsasmarketingdirectorcaa citations mla style paul j sekhri joins perseptive biosystems as marketing director analytical products the free library  pr newswire association llc  jul  httpswwwthefreelibrarycompauljsekhrijoinsperseptivebiosystemsasmarketingdirectorca chicago style the free library sv paul j sekhri joins perseptive biosystems as marketing director analytical products retrieved jul   from httpswwwthefreelibrarycompauljsekhrijoinsperseptivebiosystemsasmarketingdirectorca apa style paul j sekhri joins perseptive biosystems as marketing director analytical products nd the free library  retrieved jul   from httpswwwthefreelibrarycompauljsekhrijoinsperseptivebiosystemsasmarketingdirectorca cambridge mass may  prnewswire  paul j sekhri has joined perseptive biosystems inc nasdaq pbio as marketing director analytical products the company announced today sekhri comes to perseptive biosystems from millipore corporation where he had been senior manager biotechnology market development sekhri will be responsible for perseptives immunodetectiontm products that combine the flowthrough characteristics of the companys perfusion chromatographyr process with the protein specific high sensitivity of immunoassays this growing portfolio includes idtm sensor cartridges realtime process monitortm rpmtm the first instrument to perform realtime immunoassays to monitor biopharmaceutical production processes such as purification and fermentation and an immunodetectiontm workstation for the research market to be introduced later this year paul sekhri adds another level of experienced biopharmaceutical marketing capabilities to our marketing team said robert b anacone senior vice president marketing and sales of perseptive biosystems we expect that his background will help establish our innovative immunodetection products as important new solutions for the biopharmaceutical industry sekhri was responsible for the successful product development and launch of millipores viresolvetm viral membrane filters he also served as european liaison of the companys biotechnology marketing efforts prior to millipore sekhri was director of marketing at zymark corporation and earlier served as marketing manager at genex corporation he began his career as a financial consultantaccount executive at dean witter reynolds sekhri received a bs degree in zoology from the university of maryland and a ms degree in anatomy from the university of maryland school of medicine sekhri was an assistant professor at towson state university where he taught undergraduate anatomy and physiology perseptive biosystems designs manufactures and markets proprietary products and systems for the purification and analysis of biomolecules these bioseparations products are designed to reduce significantly the time and cost required for the development and manufacture of biopharmaceuticals the companys current and planned products for the purification and analysis of biomolecules are based on three interrelated core technologies perfusion chromatographyr for high resolution separations of biomolecules  to  times faster than conventional chromatography immunodetectiontm for realtime immunoassays in a flowthrough cartridge format and rational surface designtm synthetic surfaces that bind biomolecules with the high specificity of antibodies   contact robert b anacone senior vpmarketing and sales of perseptive biosystems inc  pbio co perseptive biosystems inc st massachusetts in mtc su per mp  ne     edt copyright  pr newswire association llc no portion of this article can be reproduced without the express written permission from the copyright holder copyright  gale cengage learning all rights reserved article details printer friendly citelink email feedback publicationpr newswire datemay   wordsprevious articleunited healthcare reports first quarter results revenue eps up  percent in th consecutive record quarternext articlereaders digest to publish new edition in czech republic topics biotechnology industries officials and employees biotechnology industry officials and employees related articles robert a fein promoted to senior vice president finance for perseptive biosystems perseptive biosystems inc announces second quarter results perseptive biosystems announces election of dr william pounds to its board of directors perseptive biosystems inc announces the introduction of two new perfusion chromatography instruments perseptive biosystems announces award of patent for perfusive chromatography particles perseptive biosystems sues pharmacia and sepracor for patent infringement regnier phd named chief technical officer of perseptive biosystems coinventor of perfusion chromatography will lead technology efforts perseptive biosystems agrees to acquire perseptive technologies ii corporation perseptive biosystems reports results for second fiscal quarter of  perseptive biosystems realizes  million from selling portion of stock in millennium pharmaceuticals publications by namepublications by dateauthorsliterature ad eo pt uz before      a b c d e f g h i j k l m n o p q r s t u v w x y z a b c d e f g h i j k l m n o p q r s t u v w x y z terms of use  copyright   farlex inc  feedback  for webmasters   paul j sekhri msc executive profile  biography  bloomberg july    am et pharmaceuticals company overview of lycera corp snapshotpeople  overviewboard memberscommittees executive profile paul j sekhri mscchief executive officer president and director lycera corpagetotal calculated compensationthis person is connected to  board members in  different organizations across  different industriessee board relationships background mr paul j sekhri msc has been chief executive officer and president at lycera corp since february   mr sekhri has been an operating partner at highline therapeutics since february  he has extensive business experience as an executive in the life sciences industry and has venture capital experience in the life sciences industry prior to joining lycera mr sekhri was the senior vice president integrated care at sanofi sa from april  to january   mr sekhri founded cerimon pharmaceuticals inc in  he was venture partner at mpm bioventures iv lp from december  to january  he served as the president and chief executive officer of cerimon pharmaceuticals inc mr sekhri served as director of strategic marketing and business development for the applied microbiology division of emd millipore corporation he served as chief strategy officer and group executive vice president of global business development of teva pharmaceutical industries limited since june   until march  he served as venture partner at mpm capital prior to joining teva he spent five years from january  to may  as operating partner and head of the biotechnology operating group at tpg biotech the life sciences venture capital arm of tpg capital where he was responsible for a portfolio of more than  life sciences companies he served as partner at sprout group he served as president and chief business officer at ariad pharmaceuticals inc from october  to december  he served as an executive director at cerimon pharmaceuticals inc he worked at novartis ag zymark corporation and perseptive biosystems inc he has been the chairman of the board and director of topas therapeutics gmbh since april   mr sekhri has been the chairman of the board of supervisory directors and member of the board of supervisory directors at pharming group nv since may   and april   respectively mr sekhri serves as director at ascendancy healthcare inc he serves as director at the irvington institute for immunological research he serves as director at preferredtime inc he has been a trustee at cancer research institute inc since october  he has been a director at apt pharmaceuticals inc since december  and lycera corp since february   he has been a director of nivalis therapeutics inc since february   he has been a director at veeva systems inc since july  he has been an independent director at enumeral biomedical holdings inc since december   he served as an independent director at aryx therapeutics inc from september  to march   he served as a trustee of carnegie hall corporation he served as a director of kai pharmaceuticals inc and macrogenics inc from january  to may  he served as a director of intercept pharmaceuticals inc from january  to september  and director of tandem diabetes care inc from may  to may  he served as a director at biodel inc from january  to november   he served as a member of supervisory board of affectis pharmaceuticals ag he served as independent director at cita neuropharmaceuticals inc since april   mr sekhri received his ms in clinical anatomy and neuroscience at the university of maryland school of medicine in  and his bs in molecular biology mr sekhri received a bs in zoology of maryland school of medicineread full background corporate headquarters  plymouth roadann arbor michigan united statesphone fax  board members memberships directorpreferredtime incdirectorthe irvington institute for immunological researchdirectorascendancy healthcare incpresentdirectorapt pharmaceuticals incpresenttrusteecancer research institute incpresentdirectorveeva systems incpresentindependent directorenumeral biomedical holdings incpresentchief executive officer president and directorlycera corppresentdirectornivalis therapeutics incpresentchairman of the boardtopas therapeutics gmbh education ms university of maryland school of medicinebs university of maryland school of medicine other affiliations mpm capitalsprout groupariad pharmaceuticals incemd millipore corporationperseptive biosystems incpharming group nvzymark corporationteva pharmaceutical industries limitednovartis agmacrogenics incaryx therapeutics incmpm bioventures iv lpcita neuropharmaceuticals inccarnegie hall corporationuniversity of maryland school of medicinekai pharmaceuticals incapt pharmaceuticals inccancer research institute incintercept pharmaceuticals incaffectis pharmaceuticals agpreferredtime inccerimon pharmaceuticals incthe irvington institute for immunological researchbiodel incveeva systems incnivalis therapeutics incenumeral biomedical holdings inctpg biotechascendancy healthcare inctopas therapeutics gmbhhighline therapeutics annual compensation there is no annual compensation data available stocks options there is no stock options data available total compensation there is no total compensation data available request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup competitor compensationthere is no competitor compensation data available sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact lycera corp please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close paul sekhri senior vice president of integrated care sanofi timesjavascript is disabled market profiles login sign up login sign up   edit person paul sekhri senior vice president of integrated care at sanofi location new york ny add to my lists claim share copy the following code on your pageblog suggested widget size mobile desktop paul sekhri senior vice president of integrated care at sanofi location new york ny add to my lists claim share copy the following code on your pageblog suggested widget size mobile desktop mr paul j sekhri serves as senior vice president of integrated care at sanofi where he leads the creation of innovative solutions and business models to meet patient needs mr sekhri served as group executive vice president global business development and chief strategy officer at teva pharmaceutical industries ltd since june   mr sekhri is an advisor to the brookings global health financing initiative mr sekhri served as the managing director and operating partner at tpg biotech where he was responsible for a portfolio of more than  life science firms he joined tpg biotech in january  and has previously served as the head of biotech ops group during his tenure he served on the board of five tpg healthcare companies including as chairman of a portfolio company in the branded generics space and as consulting advisor for diverse other life science companies within the portfolio mr sekhri has over  years of operational experience in the life sciences industry including business development business strategy general management drug development and commercial strategy mr sekhri founded cerimon pharmaceuticals inc in  and served as president and chief executive officer since  he served in management positions with several lifesciences companies including millipore corporation perseptive biosystems inc and zymark corporation and northeast consulting resources inc mr sekhri served as director of strategic marketing and business development for the applied microbiology division at millipore corporation he served as president and chief business officer of ariad pharmaceuticals inc from october  to december  he served as venture partner of mpm capital and mpm bioventures iv lp from august  to january  mr sekhri held various positions with novartis ag including its senior vice president and head of global search and evaluation business development and licensing he served as head of global search and evaluation and head of global earlycommercial development of novartis pharma ag from august  to  in  mr sekhri joined the sprout group where he was a partner for healthcare technology investments from december  to september  at novartis mr sekhri served as a member of the top seniormanagement decisionmaking teams his department led the development and implementation of novartis’ global disease area strategy mr sekhri also had global responsibility for providing commercial and market input into the development of new drugs emerging from research at novartis he has been a director of veeva systems inc since july  he serves as an executive director of cerimon pharmaceuticals inc mr sekhri has been an independent director of cita neuropharmaceuticals inc since april   he serves as an independent director of patientsafe solutions and tandem diabetics he is the chairman at moksha pharmaceuticals inc mr sekhri has been a director of apt pharmaceuticals inc since december  he serves as a board observer at tb alliance and ims health inc mr sekhri serves as a director of preferredtime inc kai pharmaceuticals inc and connecticut he serves as a member of the advisory board for the bioexec institute inc mr sekhri has been a trustee of the cancer research institute inc since october  he serves as director of the irvington institute for immunological research mr sekhri served as a member of supervisory board at affectis pharmaceuticals ag he served as a director of intercept pharmaceuticals inc until august   mr sekhri served as director of biodel inc from january  to november   he served as a director of macrogenics inc he served as director of aryx therapeutics inc from september  to march   mr sekhri served as trustee of carnegie hall from  to   companies in career na related markets  colleagues  related investments alias na industry rd in biotech environmental and various industries no marketing product yet tags biotechnology pharmaceutical industry biopharmaceuticals topics of influence web site na careers achievements investments related people edit view all paul sekhricareer  jul veeva systems board member  sanofi senior vice president of integrated care  apt pharmaceuticals inc board member competencies edit view all paul sekhrieducation   university of maryland school of medicine university of maryland school of medicine edit paul sekhriachievements and recognitions add milestone no milestones has been recorded for paul sekhri edit paul sekhrilinks add link no links has been recorded for paul sekhri paul sekhriinvestmentsacquisitions no investments has been recorded for paul sekhri view all paul sekhriinvestments representing others patientsafe solutions representing tpg growth since mar company status private paul sekhrirelated people colleagues at sanofi suresh kumar evp of external affairs may olivier brandicourt chief executive officer feb katherine bowdish vice president global rd and head of sunrise feb olivier charmeil executive vice president vaccines jan view all paul sekhrirecommended market profiles  telemedicine  or more employees  companies social media marketing chiefmarteccom    employees  companies big data universe list of lists  or more employees  companies aggregated marketing technology  or more employees  companies shared economy landscape jeremiah owyang  or more employees  companies inside sales landscape  or more employees  companies paul sekhri  tpg nv  zoominfocom enumeral appoints paul j sekhri to its board of directors  business wire enumeral appoints paul j sekhri to its board of directors february    am eastern standard time cambridge massbusiness wireenumeral biomedical holdings inc otcqb enum announced today it appointed paul j sekhri to its board of directors mr sekhri is an accomplished industry executive with more than  years of experience in life sciences strategy corporate development and corporate finance having served in senior leadership positions at several pharmaceutical companies including novartis teva and sanofi he is currently president and chief executive officer of lycera and he also serves on its board of directors “paul has significant experience in developing strategic relationships and corporate collaborations for biopharmaceutical companies through both management and board roles we welcome his contributions to our board and the guidance he provides our management team” said arthur h tinkelenberg phd president and chief executive officer of enumeral john j rydzewski executive chairman of enumeral added “paul adds important biopharmaceutical industry experience to our team and his successful track record of service as an independent director of public biotech companies will greatly benefit enumeral in achieving our strategic and operational objectives on behalf of our shareholders” “i am delighted to join enumeral’s board of directors and appreciate the opportunity to work with them in support of the company’s internal pipeline development and strategic partnering activities” said mr sekhri “enumeral is in a unique position to advance immunotherapy discovery and development having assembled an exceptional management team and a platform to elucidate fundamental knowledge on how immunotherapies work in each patient” prior to joining lycera mr sekhri was senior vice president integrated care at sanofi and before that he served as group executive vice president global business development and chief strategy officer at teva pharmaceutical industries prior to this mr sekhri was operating partner and head biotech operations group at tpg biotech where he was responsible for a portfolio of more than  life science firms previously mr sekhri was founder president and chief executive officer of cerimon pharmaceuticals and before cerimon he was president and chief business officer of ariad pharmaceuticals he also held senior positions at novartis including senior vice president and head global search and evaluation and ma mr sekhri is also a director of veeva systems and has served as a director on numerous private and public company boards including kai pharmaceuticals intercept pharmaceuticals macrogenics patientsafe solutions and tandem diabetes and as a board advisor to ims health he serves on the board of trustees for the nonprofit cancer research institute and on the industry advisory boards of the michael j fox foundation the tb alliance and the tectonic theatre project mr sekhri received a bs from the university of maryland and completed postgraduate studies in clinical anatomy and neuroscience at the university of maryland school of medicine about enumeral enumeral is discovering and developing novel antibody immunotherapies that help the immune system attack diseased cells we believe we have a unique ability to extensively interrogate the human immune microenvironment for candidate selection and validation we believe our unique capabilities enable us to measure drug effects in a patientspecific manner providing the basis for developing bestinclass product candidates based on a fundamental understanding of how immunotherapies work in each patient we are building a pipeline of immunomodulators for the treatment of cancer and inflammatory diseases and leveraging the breadth of our technology through strategic collaborations httpwwwenumeralcom forward looking statements disclosure this press release contains certain “forwardlooking statements” within the meaning of the private securities litigation reform act of  as amended such statements reflect current beliefs of enumeral biomedical holdings inc “enumeral” with respect to future events and involve known and unknown risks uncertainties and other factors affecting operations market growth services products and licenses no assurances can be given regarding the achievement of future results and although enumeral believes that the expectations reflected in these forwardlooking statements are based on reasonable assumptions actual results may differ from the assumptions underlying the statements that have been made regarding anticipated events more detailed information about enumeral and risk factors that may affect the realization of forwardlooking statements including forwardlooking statements in this press release is set forth in enumeral’s filings with the securities and exchange commission enumeral urges investors and security holders to read those documents free of charge at the commission’s website at httpwwwsecgov forwardlooking statements speak only as to the date they are made and except for any obligation under the us federal securities laws enumeral undertakes no obligation to publicly update any forwardlooking statement as a result of new information future events or otherwise contacts macdougall biomedical communicationscharles liles clilesmacbiocomcomorheather savelle hsavellemacbiocomcom release summary enumeral appointed paul j sekhri to its board of directors he brings experience in strategy corporate development and finance having served in senior leadership at many pharmaceutical companies contacts macdougall biomedical communicationscharles liles clilesmacbiocomcomorheather savelle hsavellemacbiocomcom search advanced news search advanced news search log in sign up